Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482252 | 1.00 | LMNA (0.40) | LMNAPOLBKMT2AALDH1A1HTT | |
| SCHEMBL12540389 | 0.91 | ALDH1A1 (0.38) | LMNAPOLBKMT2AALDH1A1HTT | |
| SCHEMBL2401096 | 0.91 | ALDH1A1 (0.38) | LMNAPOLBKMT2AALDH1A1HTT | |
| SCHEMBL103478 | 0.84 | POLB (0.47) | LMNAPOLBKMT2AALDH1A1HTT | |
| SCHEMBL23890495 | 0.80 | LMNA (0.56) | LMNAPOLBKMT2AALDH1A1HTT | |
| SCHEMBL3196032 | 0.80 | POLB (0.59) | LMNAPOLBKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL23573569 | 0.80 | POLB (0.59) | LMNAPOLBKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL3196038 | 0.80 | POLB (0.59) | LMNAPOLBKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL23573567 | 0.80 | POLB (0.59) | LMNAPOLBKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL13328885 | 0.80 | BTK (0.51) | KMT2AEPHX1L3MBTL1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | claimed |
| EP-2066645-A2 | 2 AMINO-PYRIMIDINE DERIVATIVES AS H4 RECEPTOR ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | UCB Pharma S.A. (BE) | 2009-06-10 | — | — | EP | claimed |
| WO-2008031556-A2 | 2 AMINO-PYRIMIDINE DERIVATIVES AS H4 RECEPTOR ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | UCB PHARMA, S.A. (BE) | 2008-03-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | HRH4, HRH2, HRH3 | LMNA 3550/4885POLB 2713/4885KMT2A 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.